Cancer drug trial pulled before it even started
NCT ID NCT05845307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if the drug TTI-101 could slow tumor growth in people with HPV-negative head and neck cancer before they had surgery. It was designed for patients with stage II to IV cancer that could be removed. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers
- Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?